FDA-approved changes to Danco's abortion drug Mifeprex allow use 70 days into pregnancy

The US Food and Drug Administration has approved new labeling for Mifeprex (mifepristone), allowing the abortion drug to be used through 70 days of pregnancy rather than the previous 49 days.

USA-based Danco Laboratories announced that the regulator had approved changes which include revisions to the prescribing information, patient medication guide, patient agreement form and prescriber agreement form.

These revisions reflect what Danco calls the ‘most current clinical practices and safety and efficacy data for Mifeprex’.